RBX1
ENSG00000100387
Target class
Enzyme
Chromosome
22
Approved drugs
4
Clinical candidates (approved and in development)
5
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- RBX1
- Gene name
- Ring-box 1
- Gene symbol
- RBX1
- Protein name
- E3 ubiquitin-protein ligase RBX1 (EC 2.3.2.27) (EC 2.3.2.32) (E3 ubiquitin-protein transferase RBX1) (Protein ZYP) (RING finger protein 75) (RING-box protein 1) (Rbx1) (Regulator of cullins 1) (ROC1) [Cleaved into: E3 ubiquitin-protein ligase RBX1, N-terminally processed (E3 ubiquitin-protein transferase RBX1, N-terminally processed)]
- ROC1
- RNF75
- BA554C12.1
- Gene biotype
- Protein coding
- Gene family
- Ring finger proteins|SCF complex core subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 169.61
- Tissue specificity (Gini)
- 0.156
- Tissue specificity (tau)
- 0.59
- KEGG gene identifiers
- hsa:9978
- Protein interaction confidence
- 0.898049
- Protein interaction partners
- 247
- R-HSA-110314
- R-HSA-1170546
- R-HSA-1234176
- R-HSA-180585
- R-HSA-195253
- R-HSA-2122947
- R-HSA-2644606
- R-HSA-2644607
- R-HSA-2894862
- R-HSA-4641258
- R-HSA-5610780
- R-HSA-5610783
- R-HSA-5610785
- R-HSA-5632684
- R-HSA-5658442
- R-HSA-5696394
- R-HSA-5696395
- R-HSA-5696400
- R-HSA-6781823
- R-HSA-6781827
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-68949
- R-HSA-69601
- R-HSA-8854050
And 16 more, listed on the interactive page.
- End position
- 40973539
- Start position
- 40951277
- Chromosome
- 22
- Strand
- Forward
- Cytoplasm . Nucleus .
- Nucleoplasm
Publication evidence
- PubMed 11027288
- Tissue specificity (tau)
- 0.589765
- Expression inequality (Gini)
- 0.156483
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 169.61
- Cells - Cultured fibroblasts
- 117.93
- Brain - Spinal cord (cervical c-1)
- 114.31
- Brain - Cerebellar Hemisphere
- 97.83
- Nerve - Tibial
- 90.23
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes169.61
- Cells - Cultured fibroblasts117.93
- Brain - Spinal cord (cervical c-1)114.31
- Brain - Cerebellar Hemisphere97.83
- Nerve - Tibial90.23
- Cervix - Ectocervix89.17
- Brain - Frontal Cortex (BA9)88.59
- Thyroid85.3
- Brain - Hypothalamus84.31
- Cervix - Endocervix82.95
- Lung82.89
- Artery - Coronary82.23
- Artery - Aorta81.66
- Uterus80.91
- Esophagus - Mucosa79.48
- Brain - Cerebellum79.45
- Vagina77.88
- Artery - Tibial76.9
- Brain - Substantia nigra76.8
- Brain - Anterior cingulate cortex (BA24)76.46
- Skin - Sun Exposed (Lower leg)74.69
- Fallopian Tube74.67
- Skin - Not Sun Exposed (Suprapubic)74.44
- Spleen72.46
- Adipose - Subcutaneous71.72
And 29 more, listed on the interactive page.
- GO:0000165
- GO:0000209
- GO:0006283
- GO:0006511
- GO:0006513
- GO:0006974
- GO:0007283
- GO:0016485
- GO:0016567
- GO:0031146
- GO:0032436
- GO:0032480
- GO:0034599
- GO:0034644
- GO:0042110
- GO:0042770
- GO:0043123
- GO:0043124
- GO:0043161
- GO:0043687
- GO:0044314
- GO:0045116
- GO:0045724
- GO:0045732
- GO:0045879
And 13 more, listed on the interactive page.
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005794
- GO:0005829
- GO:0019005
- GO:0031461
- GO:0031462
- GO:0031463
- GO:0031464
- GO:0031465
- GO:0031466
- GO:0031467
- GO:0080008
- GO:0090734
- GO:0004842
- GO:0005515
- GO:0019788
- GO:0031625
- GO:0034450
- GO:0060090
- GO:0061629
- GO:0061630
- GO:0061663
- GO:0097602
Related records
Trials (1,854)
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- [Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]
- 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting
- 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
- A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
- A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
Drugs (5)
- Iberdomide CRL4(CRBN) E3 ubiquitin ligase modulator
- Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
- Lenalidomide hydrochloride monohydrate CRL4(CRBN) E3 ubiquitin ligase modulator
- Pomalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor
- Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor